Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Elanco has said it is prepared for off-patent competition, after Huvepharma was recently given the green light by the US FDA for the first generic monensin for certain indications in cattle and goats.
Bimeda Animal Health has received US approval for generic injectable treatments for swine and cattle.
US pet medication developer and distributor PetIQ believes it can help recent acquisition Perrigo Animal Health return to annual growth.
European authorities have paved the way for Virbac to gain authorization of Evicto – a generic antiparasitic for cats and dogs.
Dutch company Curados has signed a worldwide exclusive agreement with TBD-Biodiscovery for the development and synthesis of five active pharmaceutical ingredients (APIs) in the animal health space.
Florida-based Modern Veterinary Therapeutics (MVT) has launched its generic Medetomidine Hydrochloride injection (1mg/ml) in the US.
PetIQ is to acquire veterinary generics specialist Perrigo Animal Health – a deal that underlines the growing importance of a multi-channel approach to selling companion animal drugs.
Vetoquinol has launched a beef-flavored chewable tablet for inflammation and osteoarthritis issues in dogs.
The US FDA has recently handed out generic approvals to three companies for both livestock and pet products.
Ashish Life Science has raised INR450 million ($6.3 million) in a series A funding found, which will allow it to expand its Europe, Australia and South Africa.
French firm Ceva Santé Animale is launching MilbeGuard (milbemycin oxime) flavored tablets in the US.
Pharmgate Animal Health has introduced Deracin (chlortetracycline) to control two of the most costly and challenging diseases in the US cattle industry.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.